Junji Furuse - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara , Mustafa Özgüroğlu , Yung‐Jue Bang +97 more

2018 The Lancet 1262 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,455
Institution: Kyorin University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-0663-6117

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.